Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘The White Lotus’ sparked online interest in risky anxiety pills, study says - 2Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- 3She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- 4African Forests Have Become a Source of Carbon Emissions
- 5Nations for Rock Climbing
- Financial plan Cordial Home Redesigns That Add Worth
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Here's what can happen if you drive under the influence of pot
- An Ideal Getaway - Spots for Solo Travel
- Astronomers spot white dwarf star creating a colorful shockwave
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Vote in favor of your Number one method for praising a birthday
- Make your choice for the bird that catches your heart!
